Published in AIDS on January 14, 2011
Monocyte maturation, HIV susceptibility, and transmigration across the blood brain barrier are critical in HIV neuropathogenesis. J Leukoc Biol (2012) 1.22
Longitudinal study of emerging mental health concerns in youth perinatally infected with HIV and peer comparisons. J Dev Behav Pediatr (2012) 1.20
Neuroimaging markers of human immunodeficiency virus infection in South Africa. J Neurovirol (2012) 0.95
Monocytes mediate HIV neuropathogenesis: mechanisms that contribute to HIV associated neurocognitive disorders. Curr HIV Res (2014) 0.89
Osteoimmunopathology in HIV/AIDS: A Translational Evidence-Based Perspective. Patholog Res Int (2011) 0.89
HIV clades B and C are associated with reduced brain volumetrics. J Neurovirol (2013) 0.88
In vitro downregulation of matrix metalloproteinase-9 in rat glial cells by CCR5 antagonist maraviroc: therapeutic implication for HIV brain infection. PLoS One (2011) 0.84
A Bivalent Ligand Targeting the Putative Mu Opioid Receptor and Chemokine Receptor CCR5 Heterodimers: Binding Affinity versus Functional Activities. Medchemcomm (2013) 0.81
Interactions of HIV and drugs of abuse: the importance of glia, neural progenitors, and host genetic factors. Int Rev Neurobiol (2014) 0.81
Soluble and cell-associated insulin receptor dysfunction correlates with severity of HAND in HIV-infected women. PLoS One (2012) 0.81
Cognitive dysfunction among HIV positive and HIV negative patients with psychosis in Uganda. PLoS One (2012) 0.80
Methamphetamine and inflammatory cytokines increase neuronal Na+/K+-ATPase isoform 3: relevance for HIV associated neurocognitive disorders. PLoS One (2012) 0.80
Effect of morphine and SIV on dendritic cell trafficking into the central nervous system of rhesus macaques. J Neurovirol (2013) 0.80
Loss of CCR2 expressing non-classical monocytes are associated with cognitive impairment in antiretroviral therapy-naïve HIV-infected Thais. J Neuroimmunol (2015) 0.79
Factors related to HIV-associated neurocognitive impairment differ with age. J Neurovirol (2014) 0.78
Expression of mannose binding lectin in HIV-1-infected brain: implications for HIV-related neuronal damage and neuroAIDS. Neurobehav HIV Med (2011) 0.77
HIV-associated neurocognitive disorders: perspective on management strategies. Drugs (2013) 0.77
Interaction of drugs of abuse and microRNA with HIV: a brief review. Front Microbiol (2015) 0.76
HIV associated dementia and HIV encephalitis II: Genes on chromosome 22 expressed in individually microdissected Globus pallidus neurons (Preliminary analysis). Bioinformation (2011) 0.76
Chronic SIV and morphine treatment increases heat shock protein 5 expression at the synapse. J Neurovirol (2015) 0.75
Related or not? Development of spontaneous Creutzfeldt-Jakob disease in a patient with chronic, well-controlled HIV: A case report and review of the literature. SAGE Open Med Case Rep (2016) 0.75
HIV-1 envelope accessible surface and polarity: clade, blood, and brain. Bioinformation (2011) 0.75
The Role of HIV Infection in Neurologic Injury. Brain Sci (2017) 0.75
Effects of Morphine on Behavioral Task Performance in SIV-Infected Rhesus Macaques. J Neuroimmune Pharmacol (2016) 0.75
The association between physical activity and cognition in men with and without HIV infection. HIV Med (2017) 0.75
Prevalence and correlates for ADHD and relation with social and academic functioning among children and adolescents with HIV/AIDS in Uganda. BMC Psychiatry (2017) 0.75
Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med (2009) 28.62
Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology (2005) 21.67
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol (2007) 18.62
Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology (1993) 16.92
Updated research nosology for HIV-associated neurocognitive disorders. Neurology (2007) 16.18
Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature (1996) 15.91
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science (2010) 14.91
Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep (2009) 11.30
Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science (2010) 10.69
Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol (2008) 6.91
Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol (2006) 6.20
Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature (2001) 5.60
The AIDS dementia complex: I. Clinical features. Ann Neurol (1986) 5.22
Interrater reliability of clinical ratings and neurocognitive diagnoses in HIV. J Clin Exp Neuropsychol (2004) 5.18
Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS (2010) 4.41
CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity. Nat Neurosci (2001) 4.12
Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature (1994) 3.87
Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One (2008) 3.85
Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol (2005) 3.69
Common genetic variation and the control of HIV-1 in humans. PLoS Genet (2009) 3.68
MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology (2007) 3.24
The equilibrative nucleoside transporter family, SLC29. Pflugers Arch (2003) 3.00
Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS (2009) 2.88
Maintaining the integrity of human immunodeficiency virus sequence databases. J Virol (1996) 2.68
HIV-infected subjects with the E4 allele for APOE have excess dementia and peripheral neuropathy. Nat Med (1998) 2.68
Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet (1998) 2.67
The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci (2002) 2.53
Apolipoprotein (apo) E4 enhances HIV-1 cell entry in vitro, and the APOE epsilon4/epsilon4 genotype accelerates HIV disease progression. Proc Natl Acad Sci U S A (2008) 2.38
HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci U S A (2002) 2.31
Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS (2008) 2.21
Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nat Rev Immunol (2010) 2.20
Neurologic complications of HIV disease and their treatment. Top HIV Med (2010) 2.14
Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS (2007) 2.09
High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol (1999) 2.08
Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol (2003) 2.07
Immunohistochemical localization of human and simian immunodeficiency viral antigens in fixed tissue sections. Am J Pathol (1987) 1.92
Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol (2008) 1.90
Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon. J Biol Chem (1999) 1.90
A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology (2007) 1.90
Behavioral risk exposure and host genetics of susceptibility to HIV-1 infection. J Infect Dis (2005) 1.89
Induction of pathogenic sets of genes in macrophages and neurons in NeuroAIDS. Am J Pathol (2003) 1.87
Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol (2004) 1.87
Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology (2003) 1.83
Human immunodeficiency virus type 1 env evolves toward ancestral states upon transmission to a new host. J Virol (2006) 1.82
Current concepts in the assessment and treatment of hepatic encephalopathy. QJM (2009) 1.82
Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol (2004) 1.79
Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV neuroAIDS. J Clin Invest (2005) 1.78
Age, apolipoprotein E4, and the risk of HIV dementia: the Hawaii Aging with HIV Cohort. J Neuroimmunol (2004) 1.78
Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol (2009) 1.75
Comparative study of methods for detecting sequence compartmentalization in human immunodeficiency virus type 1. J Virol (2007) 1.71
HIV-1 associated dementia: symptoms and causes. Retrovirology (2006) 1.70
Circulating proviral HIV DNA and HIV-associated dementia. AIDS (2005) 1.68
HIV encephalitis, proviral load and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. Brain (1998) 1.65
Neuropathologies in transgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycycline. Am J Pathol (2003) 1.62
Early penetration of the blood-brain-barrier by HIV. Neurology (1988) 1.62
Methamphetamine enhances HIV infection of macrophages. Am J Pathol (2008) 1.60
Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain (2006) 1.60
HIV vaccine development by computer assisted design: the GAIA vaccine. Vaccine (2005) 1.56
Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals. Neurology (2002) 1.55
HIV-1-associated dementia: a basic science and clinical perspective. AIDS Read (2002) 1.54
Role of macrophage activation in the pathogenesis of Alzheimer's disease and human immunodeficiency virus type 1-associated dementia. Eur J Clin Invest (2000) 1.53
Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active anti-retroviral therapy. Acta Neuropathol (2006) 1.52
Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS. Neurosci Biobehav Rev (2008) 1.52
Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology (2004) 1.49
Phylodynamic analysis of human immunodeficiency virus type 1 in distinct brain compartments provides a model for the neuropathogenesis of AIDS. J Virol (2005) 1.49
Opioid G protein-coupled receptors: signals at the crossroads of inflammation. Trends Immunol (2003) 1.45
Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV-1 Tat transgenic mice. Glia (2008) 1.42
HIV DNA and cognition in a Thai longitudinal HAART initiation cohort: the SEARCH 001 Cohort Study. Neurology (2009) 1.41
Transfer of neuropathogenic simian immunodeficiency virus with naturally infected microglia. Am J Pathol (1995) 1.39
Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine. BMC Neurosci (2001) 1.39
Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis (2005) 1.35
The comorbidity of HIV-associated neurocognitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. J Neuroimmune Pharmacol (2008) 1.31
Patterns of gene dysregulation in the frontal cortex of patients with HIV encephalitis. J Neuroimmunol (2004) 1.29
HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther (2004) 1.29
Tumor necrosis factor alpha inhibits glutamate uptake by primary human astrocytes. Implications for pathogenesis of HIV-1 dementia. J Biol Chem (1996) 1.27
Astrocyte specific viral strains in HIV dementia. Ann Neurol (2004) 1.26
A model of human immunodeficiency virus encephalitis in scid mice. Proc Natl Acad Sci U S A (1993) 1.25
Independent evolution of HIV type 1 in different brain regions. AIDS Res Hum Retroviruses (1999) 1.25
Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users. Neurology (2006) 1.23
Protecting HIV databases. Nature (1995) 1.22
The renaissance in HIV vaccine development--future directions. N Engl J Med (2010) 1.19
Human immunodeficiency virus (HIV) infection of human macrophages is increased by dopamine: a bridge between HIV-associated neurologic disorders and drug abuse. Am J Pathol (2009) 1.18
The impact of improved self-efficacy on HIV viral load and distress in culturally diverse women living with AIDS: the SMART/EST Women's Project. AIDS Care (2005) 1.17
Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology (2006) 1.16
Escalating dose-multiple binge methamphetamine exposure results in degeneration of the neocortex and limbic system in the rat. Exp Neurol (2007) 1.15
Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. J Neurovirol (2005) 1.14
Age as a determinant of survival in HIV infection. J Clin Epidemiol (2001) 1.14
Cerebrospinal fluid treponemal antibodies in untreated early syphilis. Arch Neurol (1995) 1.14
Unique HIV type 1 V3 region sequences derived from six different regions of brain: region-specific evolution within host-determined quasispecies. AIDS Res Hum Retroviruses (1998) 1.14
Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J Neurosci Res (2009) 1.14
Alterations in blood-brain barrier function by morphine and methamphetamine. Ann N Y Acad Sci (2006) 1.13
Cocaine-mediated enhancement of virus replication in macrophages: implications for human immunodeficiency virus-associated dementia. J Neurovirol (2007) 1.13
Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos (2008) 1.12
Elevated expression of IFN-gamma in the HIV-1 infected brain. Front Biosci (2004) 1.12
Neurologic presentations of AIDS. Neurol Clin (2010) 1.12
APOE epsilon4 and MBL-2 O/O genotypes are associated with neurocognitive impairment in HIV-infected plasma donors. AIDS (2010) 1.12
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol (2010) 5.03
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 4.80
Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol (2009) 4.73
Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell (2006) 4.13
PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology (2013) 3.02
Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav (2007) 2.98
Molecular biology, epidemiology, and pathogenesis of progressive multifocal leukoencephalopathy, the JC virus-induced demyelinating disease of the human brain. Clin Microbiol Rev (2012) 2.92
Age-associated predictors of medication adherence in HIV-positive adults: health beliefs, self-efficacy, and neurocognitive status. Health Psychol (2007) 2.62
The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci (2002) 2.53
Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol (2010) 2.48
Atypical manifestations and poor outcome of herpes simplex encephalitis in the immunocompromised. Neurology (2012) 2.30
Prevalence of human immunodeficiency virus-associated cognitive impairment in a group of Hispanic women at risk for neurological impairment. J Neurovirol (2006) 2.27
Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS (2007) 2.09
Distributions of exons and introns in the human genome. In Silico Biol (2004) 2.06
Persistence of HIV-associated cognitive impairment, inflammation, and neuronal injury in era of highly active antiretroviral treatment. AIDS (2011) 2.04
Effects of nadir CD4 count and duration of human immunodeficiency virus infection on brain volumes in the highly active antiretroviral therapy era. J Neurovirol (2010) 1.95
Ineffective phagocytosis of amyloid-beta by macrophages of Alzheimer's disease patients. J Alzheimers Dis (2005) 1.88
Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol (2004) 1.87
Synergistic increases in intracellular Ca2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat. Glia (2005) 1.86
Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol (2005) 1.81
Eccentric target sign in cerebral toxoplasmosis: neuropathological correlate to the imaging feature. J Magn Reson Imaging (2010) 1.75
NMDA receptor activation by HIV-Tat protein is clade dependent. J Neurosci (2008) 1.74
Utility of molecular and serodiagnostic tools in cerebral toxoplasmosis with and without tuberculous meningitis in AIDS patients: A study from South India. Ann Indian Acad Neurol (2010) 1.72
HIV-tat induces formation of an LRP-PSD-95- NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes. Proc Natl Acad Sci U S A (2007) 1.71
Comparative study of methods for detecting sequence compartmentalization in human immunodeficiency virus type 1. J Virol (2007) 1.71
Activated T-cells inhibit neurogenesis by releasing granzyme B: rescue by Kv1.3 blockers. J Neurosci (2010) 1.69
Lipodystrophy and dyslipidemia among patients taking first-line, World Health Organization-recommended highly active antiretroviral therapy regimens in Western India. J Acquir Immune Defic Syndr (2005) 1.64
Role of Tat protein in HIV neuropathogenesis. Neurotox Res (2009) 1.60
From Systematic Reviews to Clinical Recommendations for Evidence-Based Health Care: Validation of Revised Assessment of Multiple Systematic Reviews (R-AMSTAR) for Grading of Clinical Relevance. Open Dent J (2010) 1.60
Anemia prevalence and associated risk factors in a single-center ambulatory HIV clinical cohort. AIDS Read (2004) 1.60
Nef-mediated enhancement of virion infectivity and stimulation of viral replication are fundamental properties of primate lentiviruses. J Virol (2007) 1.58
Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J Virol (2011) 1.56
Challenges to the diagnosis and management of HIV dementia. AIDS Read (2006) 1.55
CD4-independent infection of astrocytes by human immunodeficiency virus type 1: requirement for the human mannose receptor. J Virol (2004) 1.52
Cocaine-mediated enhancement of Tat toxicity in rat hippocampal cell cultures: the role of oxidative stress and D1 dopamine receptor. Neurotoxicology (2005) 1.51
Vitamin D and multiple sclerosis: a critical review and recommendations on treatment. Acta Neurol Belg (2012) 1.46
SHIV-1157i and passaged progeny viruses encoding R5 HIV-1 clade C env cause AIDS in rhesus monkeys. Retrovirology (2008) 1.45
Lidocaine-induced seizures in patients with history of epilepsy: effect of antiepileptic drugs. Anesthesiology (2002) 1.44
HIV-1 Tat protein alters tight junction protein expression and distribution in cultured brain endothelial cells. J Neurosci Res (2003) 1.43
A multi-center blinded prospective study of urine neural thread protein measurements in patients with suspected Alzheimer's disease. J Am Med Dir Assoc (2006) 1.42
Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV-1 Tat transgenic mice. Glia (2008) 1.42
Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. Proc Natl Acad Sci U S A (2013) 1.41
Neuronal apoptosis is mediated by CXCL10 overexpression in simian human immunodeficiency virus encephalitis. Am J Pathol (2004) 1.40
Cigarette smoking and the risk of multiple sclerosis: a sibling case-control study in Isfahan, Iran. Neuroepidemiology (2011) 1.40
Estrogen attenuates gp120- and tat1-72-induced oxidative stress and prevents loss of dopamine transporter function. Synapse (2006) 1.40
Proton MRS and neuropsychological correlates in AIDS dementia complex: evidence of subcortical specificity. J Neuropsychiatry Clin Neurosci (2007) 1.39
Intracellular human immunodeficiency virus Tat expression in astrocytes promotes astrocyte survival but induces potent neurotoxicity at distant sites via axonal transport. J Biol Chem (2003) 1.38
Apoptotic death of striatal neurons induced by human immunodeficiency virus-1 Tat and gp120: Differential involvement of caspase-3 and endonuclease G. J Neurovirol (2004) 1.38
Synaptic transport of human immunodeficiency virus-Tat protein causes neurotoxicity and gliosis in rat brain. J Neurosci (2003) 1.35
Inflammation in amyotrophic lateral sclerosis spinal cord and brain is mediated by activated macrophages, mast cells and T cells. Amyotroph Lateral Scler Other Motor Neuron Disord (2004) 1.35
HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat. Brain Res (2003) 1.34
Signaling mechanisms of HIV-1 Tat-induced alterations of claudin-5 expression in brain endothelial cells. J Cereb Blood Flow Metab (2005) 1.33
HIV-Tat protein induces oxidative and inflammatory pathways in brain endothelium. J Neurochem (2003) 1.31
CXCL10-induced cell death in neurons: role of calcium dysregulation. Eur J Neurosci (2006) 1.31
HIV-1 neuropathogenesis: glial mechanisms revealed through substance abuse. J Neurochem (2006) 1.31
Neurocognition in individuals co-infected with HIV and hepatitis C. J Addict Dis (2008) 1.30
HIV-1 Tat protein upregulates inflammatory mediators and induces monocyte invasion into the brain. Mol Cell Neurosci (2003) 1.29
R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models. PLoS One (2010) 1.29
Permeability of the blood-brain barrier to HIV-1 Tat. Exp Neurol (2005) 1.28
Neurological complications of immune reconstitution in HIV-infected populations. Ann N Y Acad Sci (2010) 1.28
Extent of cerebellum, subcortical and cortical atrophy in patients with MS: a case-control study. J Neurol Sci (2009) 1.28
Temporal relationships between HIV-1 Tat-induced neuronal degeneration, OX-42 immunoreactivity, reactive astrocytosis, and protein oxidation in the rat striatum. Brain Res (2003) 1.27
The National NeuroAIDS Tissue Consortium brain gene array: two types of HIV-associated neurocognitive impairment. PLoS One (2012) 1.27
Neuroimaging correlates of HIV-associated BBB compromise. J Neuroimmunol (2004) 1.27
Immune reconstitution inflammatory syndrome and the central nervous system. Curr Opin Neurol (2011) 1.27
Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol (2011) 1.26
MPID: MHC-Peptide Interaction Database for sequence-structure-function information on peptides binding to MHC molecules. Bioinformatics (2003) 1.25
Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol (2010) 1.25
A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis. Brain (2008) 1.25
An anti-HIV-1 V3 loop antibody fully protects cross-clade and elicits T-cell immunity in macaques mucosally challenged with an R5 clade C SHIV. PLoS One (2011) 1.24
Neuropathology of HIV/AIDS with an overview of the Indian scene. Indian J Med Res (2005) 1.23
The HIV Dementia Scale: predictive power in mild dementia and HAART. J Neurol Sci (2007) 1.23
Cerebral metabolite abnormalities in human immunodeficiency virus are associated with cortical and subcortical volumes. J Neurovirol (2010) 1.22
Novel markers of oxidative stress in actively progressive HIV dementia. J Neuroimmunol (2004) 1.21
HIV-1 Tat neurotoxicity in primary cultures of rat midbrain fetal neurons: changes in dopamine transporter binding and immunoreactivity. Neurosci Lett (2005) 1.21
Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis. Ann Neurol (2011) 1.21
Neurovirological correlation with HIV-associated neurocognitive disorders and encephalitis in a HAART-era cohort. J Acquir Immune Defic Syndr (2013) 1.21
Human immunodeficiency virus type 1 in the central nervous system leads to decreased dopamine in different regions of postmortem human brains. J Neurovirol (2009) 1.20
Granzyme B mediates neurotoxicity through a G-protein-coupled receptor. FASEB J (2006) 1.19
betaA3/A1-crystallin in astroglial cells regulates retinal vascular remodeling during development. Mol Cell Neurosci (2007) 1.18
SDF-1alpha is expressed in astrocytes and neurons in the AIDS dementia complex: an in vivo and in vitro study. J Neuropathol Exp Neurol (2003) 1.17
A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes. J Neurovirol (2013) 1.16
Inflammatory changes and breakdown of microvascular integrity in early human immunodeficiency virus dementia. J Neurovirol (2004) 1.15
Evidence of platelet activation in multiple sclerosis. J Neuroinflammation (2008) 1.15
Human herpes 6 virus encephalitis complicating allogeneic hematopoietic stem cell transplantation. Neurology (2013) 1.15
Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. J Neurovirol (2005) 1.14
Increasing incidence of ischemic stroke in patients with HIV infection. Neurology (2011) 1.14
Evidence-Based Research in Complementary and Alternative Medicine III: Treatment of Patients with Alzheimer's Disease. Evid Based Complement Alternat Med (2006) 1.14
Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection. J Virol (2008) 1.14
Incidence of various cardiac arrhythmias and conduction disturbances due to high dose intravenous methylprednisolone in patients with multiple sclerosis. J Neurol Sci (2011) 1.13
Commentary on Designations of Medicines by Nigel Wiseman. Evid Based Complement Alternat Med (2005) 1.13
JC virus antibody and viremia as predictors of progressive multifocal leukoencephalopathy in human immunodeficiency virus-1-infected individuals. Clin Infect Dis (2011) 1.13
Immune reconstitution is not a prognostic factor in progressive multifocal leukoencephalopathy. J Neuroimmunol (2011) 1.12
Neurologic presentations of AIDS. Neurol Clin (2010) 1.12
Elevated expression of IFN-gamma in the HIV-1 infected brain. Front Biosci (2004) 1.12
Relative transmissibility of an R5 clade C simian-human immunodeficiency virus across different mucosae in macaques parallels the relative risks of sexual HIV-1 transmission in humans via different routes. J Infect Dis (2010) 1.12
Neurotoxic effects of the human immunodeficiency virus type-1 transcription factor Tat require function of a polyamine sensitive-site on the N-methyl-D-aspartate receptor. Brain Res (2002) 1.12